Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Current Drug Trials, Potential Breakthrough Therapies, Pharma R&D Initiatives, and Future Market Transformations

DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia Pipeline Report to explore emerging therapies, key Hemophilia Companies, and future Hemophilia treatment landscapes @ Hemophilia Pipeline Outlook Report- https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Hemophilia Pipeline Report
• On 12 September 2025, Gritgen Therapeutics Co. Ltd announced a study is a single-arm, open-label, multicenter study evaluating the efficacy and safety of GS1191-0445 injection as a single dose in Chinese subjects with hemophilia A. GS1191-0445 is an AAV8-based gene therapy vector designed to express B-domain deleted human factor VIII (FVIII) under the regulation of a human liver-specific promoter. Following a single intravenous administration, AAV8 targets hepatocytes and facilitates the specific expression and secretion of FVIII into the bloodstream.
• DelveInsight's Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment.
• The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
• Promising Hemophilia Therapies such as ELOCTA, ALPROLIX, Mim8, NNC0365-3769, MG1113, STSP-0601 for Injection, SerpinPC, Fitusiran, Esperoct andothers.

Discover how the Hemophilia treatment paradigm is evolving. Access DelveInsight's in-depth Hemophilia Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies- https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hemophilia Emerging Drugs Profile
• SerpinPC: Centessa Pharmaceuticals
SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data.

• Fitusiran: Alnylam Pharmaceuticals
Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia.

• ASC 618: ASC Therapeutics
ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration.

Get a detailed analysis of the latest innovations in the Hemophilia pipeline. Explore DelveInsight's expert-driven report today! @ Hemophilia Unmet Needs- https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hemophilia Companies
Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.

Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Hemophilia Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hemophilia Pipeline Report
• Coverage- Global
• Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
• Hemophilia Therapies- ELOCTA, ALPROLIX, Mim8, NNC0365-3769, MG1113, STSP-0601 for Injection, SerpinPC, Fitusiran, Esperoct andothers.
• Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Hemophilia drug development? Find out in DelveInsight's exclusive Hemophilia Pipeline Report-access it now! @ Hemophilia Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.